You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Article metrics

Article menu

Download PDFPDF

Research Article
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

 

Online download statistics by month:

Online download statistics by month: December 2019 to July 2025

AbstractFullPdf
Dec 2019110
Jan 2020440
Feb 202013134
Mar 202024235
Apr 202029295
May 2020404012
Jun 202022223
Jul 202020205
Aug 202018181
Sep 202034345
Oct 202028286
Nov 202020208
Dec 202017182
Jan 202128287
Feb 2021303014
Mar 202154548
Apr 202129295
May 2021171725
Jun 2021262611
Jul 202124244
Aug 2021212112
Sep 2021292913
Oct 2021313119
Nov 2021373726
Dec 2021303112
Jan 202231324
Feb 202220239
Mar 2022394214
Apr 202229309
May 2022363610
Jun 2022474922
Jul 202233367
Aug 202241416
Sep 202221821819
Oct 2022505830
Nov 2022373713
Dec 202229297
Jan 202337379
Feb 202359596
Mar 202352547
Apr 2023272915
May 2023242411
Jun 202324246
Jul 2023323221
Aug 2023343416
Sep 2023373815
Oct 202336368
Nov 2023363610
Dec 2023626213
Jan 202444457
Feb 202459599
Mar 2024444448
Apr 2024505021
May 2024363810
Jun 202434347
Jul 2024444411
Aug 202441408
Sep 2024262611
Oct 2024383914
Nov 202449507
Dec 202435368
Jan 2025383814
Feb 202521421414
Mar 2025626215
Apr 2025898910
May 2025606021
Jun 2025686816
Jul 2025110
Total27282760750